The following drugs are contra-indicated for the treatment of atrial fibrillation associated with the WPW syndrome
**Core Concept**
Atrial fibrillation associated with Wolff-Parkinson-White (WPW) syndrome is a unique clinical scenario where the standard treatment approach for atrial fibrillation is contraindicated due to the underlying accessory electrical pathway. The primary concern is preventing the enhancement of anterograde conduction through the accessory pathway, which can worsen the condition.
**Why the Correct Answer is Right**
The correct approach for WPW syndrome involves the use of drugs that block the AV node (adenosine, digoxin, beta-blockers, and non-dihydropyridine calcium channel blockers) to prevent anterograde conduction through the accessory pathway. However, this is not the case for atrial fibrillation associated with WPW syndrome, where these drugs can paradoxically worsen the condition by facilitating anterograde conduction through the accessory pathway.
**Why Each Wrong Option is Incorrect**
* **Option A:** Amiodarone can be used in WPW syndrome, but it's not the best choice for this scenario. Amiodarone can facilitate conduction through the accessory pathway in some cases.
* **Option B:** Sotalol is a beta-blocker with Class III anti-arrhythmic properties. However, in WPW syndrome, beta-blockers can also facilitate anterograde conduction through the accessory pathway, making it a poor choice.
* **Option C:** Procainamide (a Class IA anti-arrhythmic) and Flecainide (a Class IC anti-arrhythmic) are generally contraindicated in WPW syndrome due to their potential to facilitate conduction through the accessory pathway.
**Clinical Pearl / High-Yield Fact**
In WPW syndrome, the goal is to block the accessory pathway, whereas in atrial fibrillation, the goal is to slow AV nodal conduction. This fundamental difference in pathophysiology dictates the choice of treatment.
**Correct Answer: C. Procainamide (a Class IA anti-arrhythmic) and Flecainide (a Class IC anti-arrhythmic)**